SK2162002A3 - Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity - Google Patents
Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity Download PDFInfo
- Publication number
- SK2162002A3 SK2162002A3 SK216-2002A SK2162002A SK2162002A3 SK 2162002 A3 SK2162002 A3 SK 2162002A3 SK 2162002 A SK2162002 A SK 2162002A SK 2162002 A3 SK2162002 A3 SK 2162002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- inhibitor
- monoamine oxidase
- reversible
- methoxymethyl
- befloxatone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99116026A EP1078632A1 (en) | 1999-08-16 | 1999-08-16 | Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity |
PCT/EP2000/007917 WO2001012176A2 (en) | 1999-08-16 | 2000-08-08 | Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
SK2162002A3 true SK2162002A3 (en) | 2002-07-02 |
Family
ID=8238777
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK216-2002A SK2162002A3 (en) | 1999-08-16 | 2000-08-08 | Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity |
Country Status (22)
Country | Link |
---|---|
EP (2) | EP1078632A1 (tr) |
JP (1) | JP2003506485A (tr) |
KR (1) | KR20020025971A (tr) |
CN (1) | CN1370067A (tr) |
AR (1) | AR025244A1 (tr) |
AU (1) | AU6441900A (tr) |
BR (1) | BR0013282A (tr) |
CA (1) | CA2377133A1 (tr) |
CZ (1) | CZ2002554A3 (tr) |
EA (1) | EA200200117A1 (tr) |
EE (1) | EE200200062A (tr) |
HK (1) | HK1046104A1 (tr) |
HU (1) | HUP0203601A2 (tr) |
IL (1) | IL147790A0 (tr) |
IS (1) | IS6251A (tr) |
MX (1) | MXPA02001649A (tr) |
NO (1) | NO20020770L (tr) |
PL (1) | PL364865A1 (tr) |
SK (1) | SK2162002A3 (tr) |
TR (1) | TR200200376T2 (tr) |
WO (1) | WO2001012176A2 (tr) |
ZA (1) | ZA200200738B (tr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1307182E (pt) * | 2000-08-01 | 2005-08-31 | Sanofi Aventis | Composicao farmaceutica para administracao de befloxatona por via transdermica |
DE10142660A1 (de) | 2001-08-31 | 2003-03-20 | Aventis Pharma Gmbh | Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
EP1425029A4 (en) | 2001-08-10 | 2006-06-07 | Palatin Technologies Inc | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES |
DE10142663B4 (de) | 2001-08-31 | 2004-08-19 | Aventis Pharma Deutschland Gmbh | C2-Disubstituierte Indan-1-ol-Systeme |
DE10142667B4 (de) | 2001-08-31 | 2004-06-09 | Aventis Pharma Deutschland Gmbh | C2-substituierte Indan-1-ole und ihre Derivate und ihre Verwendung als Arzneimittel |
DE10142666A1 (de) | 2001-08-31 | 2003-03-20 | Aventis Pharma Gmbh | Verwendung von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
DE10142662B4 (de) | 2001-08-31 | 2004-07-08 | Aventis Pharma Deutschland Gmbh | Derivate von C2-substituierten Indan-1-ol-Systemen und ihre Verwendung als Arzneimittel |
DE10142722A1 (de) | 2001-08-31 | 2003-03-27 | Aventis Pharma Gmbh | C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
DE10142665B4 (de) | 2001-08-31 | 2004-05-06 | Aventis Pharma Deutschland Gmbh | C2-Disubstituierte Indan-1-one und ihre Derivate |
DE10142659A1 (de) | 2001-08-31 | 2003-03-20 | Aventis Pharma Gmbh | Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
DE10142661B4 (de) | 2001-08-31 | 2004-06-09 | Aventis Pharma Deutschland Gmbh | Mehrfach substituierte Indan-1-ol-Systeme und ihre Verwendung als Arzneimittel |
DE10142668A1 (de) | 2001-08-31 | 2003-03-20 | Aventis Pharma Gmbh | Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
US6932971B2 (en) | 2002-07-18 | 2005-08-23 | Cytos Biotechnology Ag | Hapten-carrier conjugates and uses thereof |
US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
DE10342672A1 (de) * | 2003-09-16 | 2005-04-21 | Bayer Chemicals Ag | Chirale Phosphane zur Verwendung in asymmetrischen Synthesen |
NZ564130A (en) * | 2005-06-02 | 2009-12-24 | Jenrin Discovery | N-propargyl-1-aminoindan compounds useful for treating obesity |
US20070078172A1 (en) * | 2005-06-16 | 2007-04-05 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2009070533A1 (en) * | 2007-11-29 | 2009-06-04 | Complegen, Inc. | Methods of inhibiting steroyl coa desaturase |
EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
CN102267990B (zh) * | 2011-06-03 | 2013-11-13 | 浙江工业大学 | 一种2,3-二氢苯并呋喃类衍生物及其制备与应用 |
EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
CN110511208B (zh) * | 2019-08-02 | 2020-08-25 | 浙江工业大学 | N-2-吡啶基-2,3-二叠氮吲哚啉类化合物及其制备与应用 |
KR20230075912A (ko) | 2021-11-23 | 2023-05-31 | 서제표 | 접이식 안경 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3153092A (en) * | 1961-07-17 | 1964-10-13 | Smith Kline French Lab | 1-methyl-2-phenylcyclopropylamine derivatives |
US3466236A (en) * | 1965-11-09 | 1969-09-09 | Eastman Kodak Co | Irradiation of aminocyclobutanones |
AU5550780A (en) * | 1979-04-26 | 1980-10-30 | Merrell Toraude Et Compagnie | Alpha-halomethyl amines |
FR2724171B1 (fr) * | 1994-09-05 | 1997-01-03 | Synthelabo | Derives de 3,3a,4,5-tetrahydro-1h-oxazolo(3,4-a)quinolein-1-one, leur preparation et leur application en therapeutique |
CZ378497A3 (cs) * | 1995-06-02 | 1998-04-15 | Synthelabo | Deriváty oxazolidinonu, způsob jejich přípravy a jejich terapeutické použití |
WO1997013768A1 (fr) * | 1995-10-11 | 1997-04-17 | Synthelabo | Composes derives d'oxazolidin-2-one, leur procede de preparation et leur application en therapeutique |
-
1999
- 1999-08-16 EP EP99116026A patent/EP1078632A1/en not_active Withdrawn
-
2000
- 2000-08-08 EP EP00951508A patent/EP1210080A2/en not_active Withdrawn
- 2000-08-08 JP JP2001516522A patent/JP2003506485A/ja not_active Withdrawn
- 2000-08-08 CN CN00811699A patent/CN1370067A/zh active Pending
- 2000-08-08 HU HU0203601A patent/HUP0203601A2/hu unknown
- 2000-08-08 SK SK216-2002A patent/SK2162002A3/sk unknown
- 2000-08-08 WO PCT/EP2000/007917 patent/WO2001012176A2/en not_active Application Discontinuation
- 2000-08-08 CZ CZ2002554A patent/CZ2002554A3/cs unknown
- 2000-08-08 BR BR0013282-9A patent/BR0013282A/pt not_active Application Discontinuation
- 2000-08-08 CA CA002377133A patent/CA2377133A1/en not_active Abandoned
- 2000-08-08 EE EEP200200062A patent/EE200200062A/xx unknown
- 2000-08-08 IL IL14779000A patent/IL147790A0/xx unknown
- 2000-08-08 KR KR1020027001959A patent/KR20020025971A/ko not_active Application Discontinuation
- 2000-08-08 EA EA200200117A patent/EA200200117A1/ru unknown
- 2000-08-08 TR TR2002/00376T patent/TR200200376T2/tr unknown
- 2000-08-08 PL PL00364865A patent/PL364865A1/xx not_active Application Discontinuation
- 2000-08-08 AU AU64419/00A patent/AU6441900A/en not_active Abandoned
- 2000-08-08 MX MXPA02001649A patent/MXPA02001649A/es unknown
- 2000-08-15 AR ARP000104209A patent/AR025244A1/es unknown
-
2002
- 2002-01-25 IS IS6251A patent/IS6251A/is unknown
- 2002-01-28 ZA ZA200200738A patent/ZA200200738B/xx unknown
- 2002-02-15 NO NO20020770A patent/NO20020770L/no unknown
- 2002-10-29 HK HK02107811.0A patent/HK1046104A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
NO20020770L (no) | 2002-04-16 |
BR0013282A (pt) | 2002-04-23 |
CA2377133A1 (en) | 2001-02-22 |
ZA200200738B (en) | 2003-03-26 |
IS6251A (is) | 2002-01-25 |
AR025244A1 (es) | 2002-11-13 |
HK1046104A1 (zh) | 2002-12-27 |
PL364865A1 (en) | 2004-12-27 |
IL147790A0 (en) | 2002-08-14 |
EE200200062A (et) | 2003-04-15 |
TR200200376T2 (tr) | 2002-06-21 |
CN1370067A (zh) | 2002-09-18 |
MXPA02001649A (es) | 2002-10-23 |
WO2001012176A3 (en) | 2002-03-21 |
EP1078632A1 (en) | 2001-02-28 |
EP1210080A2 (en) | 2002-06-05 |
JP2003506485A (ja) | 2003-02-18 |
NO20020770D0 (no) | 2002-02-15 |
HUP0203601A2 (hu) | 2003-02-28 |
AU6441900A (en) | 2001-03-13 |
CZ2002554A3 (cs) | 2002-05-15 |
EA200200117A1 (ru) | 2002-06-27 |
KR20020025971A (ko) | 2002-04-04 |
WO2001012176A2 (en) | 2001-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK2162002A3 (en) | Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity | |
US11839591B2 (en) | Pharmaceutical combination for the treatment of melanoma | |
AP1191A (en) | Combination therapy. | |
CN105848682A (zh) | 药物组合 | |
US20230059381A1 (en) | Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome | |
JP2008517976A (ja) | Cb1カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病1型、肥満及び関連症状の治療用の医薬組成物 | |
NO321388B1 (no) | Farmasoytisk sammensetning inneholdende en forbindelse med angiotensin II antagonistisk aktivitet i kombinasjon med en forbindelse som har insulinsensitivitetsstimulerende aktivitet, og anvendelse av samme for fremstilling av medikament. | |
AU2013248685B2 (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
JP2002308801A (ja) | うつ病、強迫疾患および精神病の組み合わせ治療 | |
KR20150036146A (ko) | Cdk4/6 억제제 및 b-raf 억제제의 제약 조합물 | |
US20160193196A1 (en) | Immediate-release tablet formulations of a thrombin receptor antagonist | |
EP2083921A2 (en) | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer | |
JP5684388B2 (ja) | 抗精神病薬誘発性体重増加を治療するための方法 | |
CZ20031387A3 (cs) | Farmaceutický prostředek, kterým je směs agonistů gama-aminomáselné kyseliny a inhibitorů aldózreduktázy | |
CA2968977A1 (en) | Compositions comprising 2-((1-(2(4-fluorophenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-one for treating schizophrenia | |
US20020165217A1 (en) | Combination treatment for anxiety and depression | |
CA2135312C (en) | Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase as a modality in cancer therapy | |
KR20090063228A (ko) | 정신분열증 치료용 비페프루녹스를 위한 적정 계획 및 이에사용하기 위한 키트 | |
US20220226300A1 (en) | A method for treating cancer with an oral dosage form of an estrogen receptor-alpha inhibitor | |
CN113425718A (zh) | 一种治疗高尿酸血症和痛风的复方制剂 | |
MX2010006520A (es) | Metodo y composicion para el tratamiento de una condicion mediada por alfa-adrenoceptor. | |
US20210308057A1 (en) | Pediatric formulation of tyrosine kinase inhibitors | |
EP2792359A1 (en) | Treatment of L-DOPA-induced dyskinesia with OPC-14523 or OPC-34712 | |
CN118252835A (en) | Application of CDK inhibitor | |
CZ20004067A3 (cs) | Nové kombinace léků N.A.R.I.(inhibitory reaktivace noradrenalinu), s výhodou reboxetinu, a pinodolu |